Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Cancer Stem Cells and Targeting Strategies.

Barbato L, Bocchetti M, Di Biase A, Regad T.

Cells. 2019 Aug 18;8(8). pii: E926. doi: 10.3390/cells8080926. Review.

2.

PYK2 promotes HER2-positive breast cancer invasion.

Al-Juboori SI, Vadakekolathu J, Idri S, Wagner S, Zafeiris D, Pearson JR, Almshayakhchi R, Caraglia M, Desiderio V, Miles AK, Boocock DJ, Ball GR, Regad T.

J Exp Clin Cancer Res. 2019 May 22;38(1):210. doi: 10.1186/s13046-019-1221-0.

3.

Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation.

Mele L, la Noce M, Paino F, Regad T, Wagner S, Liccardo D, Papaccio G, Lombardi A, Caraglia M, Tirino V, Desiderio V, Papaccio F.

J Exp Clin Cancer Res. 2019 Apr 12;38(1):160. doi: 10.1186/s13046-019-1164-5.

4.

HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.

La Noce M, Paino F, Mele L, Papaccio G, Regad T, Lombardi A, Papaccio F, Desiderio V, Tirino V.

J Exp Clin Cancer Res. 2018 Dec 3;37(1):296. doi: 10.1186/s13046-018-0978-x.

5.

A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo.

Mele L, Paino F, Papaccio F, Regad T, Boocock D, Stiuso P, Lombardi A, Liccardo D, Aquino G, Barbieri A, Arra C, Coveney C, La Noce M, Papaccio G, Caraglia M, Tirino V, Desiderio V.

Cell Death Dis. 2018 May 1;9(5):572. doi: 10.1038/s41419-018-0635-5.

6.

MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer.

Vadakekolathu J, Al-Juboori SIK, Johnson C, Schneider A, Buczek ME, Di Biase A, Pockley AG, Ball GR, Powe DG, Regad T.

Cell Death Dis. 2018 Mar 1;9(3):344. doi: 10.1038/s41419-018-0364-9.

7.

Identification and characterisation of NANOG+/ OCT-4high/SOX2+ doxorubicin-resistant stem-like cells from transformed trophoblastic cell lines.

Balahmar RM, Boocock DJ, Coveney C, Ray S, Vadakekolathu J, Regad T, Ali S, Sivasubramaniam S.

Oncotarget. 2018 Jan 11;9(6):7054-7065. doi: 10.18632/oncotarget.24151. eCollection 2018 Jan 23.

8.

Targeting cellular pathways in glioblastoma multiforme.

Pearson JRD, Regad T.

Signal Transduct Target Ther. 2017 Sep 29;2:17040. doi: 10.1038/sigtrans.2017.40. eCollection 2017. Review.

9.

Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development.

Papaccio F, Paino F, Regad T, Papaccio G, Desiderio V, Tirino V.

Stem Cells Transl Med. 2017 Dec;6(12):2115-2125. doi: 10.1002/sctm.17-0138. Epub 2017 Oct 26. Review.

10.

Identification and Isolation of Cancer Stem Cells Using NANOG-EGFP Reporter System.

Buczek ME, Reeder SP, Regad T.

Methods Mol Biol. 2018;1692:139-148. doi: 10.1007/978-1-4939-7401-6_13.

PMID:
28986894
11.

Generation of In Vitro Model of Epithelial Mesenchymal Transition (EMT) Via the Expression of a Cytoplasmic Mutant Form of Promylocytic Leukemia Protein (PML).

Di Biase A, Miles AK, Regad T.

Methods Mol Biol. 2018;1692:129-138. doi: 10.1007/978-1-4939-7401-6_12.

PMID:
28986893
12.

A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma.

Dvorkina M, Nieddu V, Chakelam S, Pezzolo A, Cantilena S, Leite AP, Chayka O, Regad T, Pistorio A, Sementa AR, Virasami A, Barton J, Montano X, Lechertier T, Brindle N, Morgenstern D, Lebras M, Burns AJ, Saunders NJ, Hodivala-Dilke K, Bagella L, De The H, Anderson J, Sebire N, Pistoia V, Sala A, Salomoni P.

Clin Cancer Res. 2016 Jul 1;22(13):3398-409. doi: 10.1158/1078-0432.CCR-15-2081. Epub 2016 Apr 13. Erratum in: Clin Cancer Res. 2017 Feb 1;23 (3):870.

13.

Cytoplasmic PML promotes TGF-β-associated epithelial-mesenchymal transition and invasion in prostate cancer.

Buczek ME, Miles AK, Green W, Johnson C, Boocock DJ, Pockley AG, Rees RC, Hulman G, van Schalkwyk G, Parkinson R, Hulman J, Powe DG, Regad T.

Oncogene. 2016 Jun 30;35(26):3465-75. doi: 10.1038/onc.2015.409. Epub 2015 Nov 9.

14.

Targeting RTK Signaling Pathways in Cancer.

Regad T.

Cancers (Basel). 2015 Sep 3;7(3):1758-84. doi: 10.3390/cancers7030860. Review.

15.

The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.

Mathieu MG, Miles AK, Ahmad M, Buczek ME, Pockley AG, Rees RC, Regad T.

Cell Death Dis. 2014 Feb 13;5:e1061. doi: 10.1038/cddis.2014.29.

16.

Molecular and cellular pathogenesis of melanoma initiation and progression.

Regad T.

Cell Mol Life Sci. 2013 Nov;70(21):4055-65. doi: 10.1007/s00018-013-1324-2. Epub 2013 Mar 27. Review.

PMID:
23532409
17.

The helicase HAGE expressed by malignant melanoma-initiating cells is required for tumor cell proliferation in vivo.

Linley AJ, Mathieu MG, Miles AK, Rees RC, McArdle SE, Regad T.

J Biol Chem. 2012 Apr 20;287(17):13633-43. doi: 10.1074/jbc.M111.308973. Epub 2012 Mar 5.

18.

SUMOylation promotes PML degradation during encephalomyocarditis virus infection.

El McHichi B, Regad T, Maroui MA, Rodriguez MS, Aminev A, Gerbaud S, Escriou N, Dianoux L, Chelbi-Alix MK.

J Virol. 2010 Nov;84(22):11634-45. doi: 10.1128/JVI.01321-10. Epub 2010 Sep 8.

19.

The tumor suppressor Pml regulates cell fate in the developing neocortex.

Regad T, Bellodi C, Nicotera P, Salomoni P.

Nat Neurosci. 2009 Feb;12(2):132-40. doi: 10.1038/nn.2251. Epub 2009 Jan 11.

PMID:
19136970
20.

The neural progenitor-specifying activity of FoxG1 is antagonistically regulated by CKI and FGF.

Regad T, Roth M, Bredenkamp N, Illing N, Papalopulu N.

Nat Cell Biol. 2007 May;9(5):531-40. Epub 2007 Apr 15.

PMID:
17435750
21.

Rabies virus P and small P products interact directly with PML and reorganize PML nuclear bodies.

Blondel D, Regad T, Poisson N, Pavie B, Harper F, Pandolfi PP, De Thé H, Chelbi-Alix MK.

Oncogene. 2002 Nov 14;21(52):7957-70.

22.

Role and fate of PML nuclear bodies in response to interferon and viral infections.

Regad T, Chelbi-Alix MK.

Oncogene. 2001 Oct 29;20(49):7274-86. Review.

23.

PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator.

Regad T, Saib A, Lallemand-Breitenbach V, Pandolfi PP, de Thé H, Chelbi-Alix MK.

EMBO J. 2001 Jul 2;20(13):3495-505.

Supplemental Content

Support Center